Id |
Subject |
Object |
Predicate |
Lexical cue |
T286 |
0-16 |
Sentence |
denotes |
• TACTIC-E Trial |
T287 |
17-71 |
Sentence |
denotes |
• Immunomodulatory agents • Multi-arm randomized trial |
T288 |
72-121 |
Sentence |
denotes |
• Pre-intensive care unit (ICU) COVID-19 patients |
T289 |
122-203 |
Sentence |
denotes |
• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care |
T290 |
204-340 |
Sentence |
denotes |
• Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days |
T291 |
341-412 |
Sentence |
denotes |
• Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020) |